0001834376-25-000074
SEC filingRevenue grew 15% YoY on higher capitation rates and census, driving net income of $7.7M compared to prior-year loss.
InnovAge reported total revenues of $236.1M for Q1 FY2026, up 15.1% YoY from $205.1M. The growth was driven by a 4.7% increase in capitation rates (Medicaid +7.9%, Medicare +3.7%) and a 9.9% rise in member months, reflecting census expansion in California, Florida, and Colorado centers. Operating expenses increased 8.5% to $227.8M, but operating income swung from a loss of $4.9M to a profit of $8.3M. Net income attributable to InnovAge was $8.0M, compared to a net loss of $4.9M in the prior period.
Cost dynamics were mixed. External provider costs rose only 1.5% to $108.9M, as a 7.6% decline in cost per participant (due to lower nursing facility utilization and pharmacy rebates) offset member month growth. Cost of care, excluding D&A, increased 19.7% to $75.9M, driven by wage inflation, higher headcount, and third-party pharmacy costs. Sales and marketing expenses grew 17.1% to $7.6M on increased headcount and marketing spend. Corporate, general and administrative expenses rose 9.9% to $30.3M, with higher compensation and software costs partially offset by lower legal fees.
The company operates two segments: PACE and All other (Senior Housing). PACE generated $235.8M in revenue, representing 99.9% of total. Center-level Contribution Margin for PACE reached $51.3M (21.8% of revenue), up from $34.4M (16.8%) in the prior year, as revenue growth outpaced direct costs. The improvement was primarily attributable to rate increases and lower external provider costs per participant. The All other segment, which includes a small Senior Housing operation, contributed $0.3M in revenue and a nominal contribution margin of $0.1M.
Management highlighted several trends and uncertainties affecting future performance. The OBBBA (July 2025) mandates reductions in federal Medicaid spending, new work requirements, and bi-annual eligibility verifications, which could decrease Medicaid enrollment and put downward pressure on capitation rates. A federal partial shutdown began October 1, 2025, but no material impact has occurred yet. Labor market pressures persist, driving wage increases and reliance on agency staffing. Tariff uncertainty may raise supply costs. Despite these headwinds, InnovAge continues to pursue growth through de novo centers (though California attestations are suspended) and tuck-in acquisitions. The company expects to invest in clinical and operational initiatives to manage cost trends and improve margins. No specific quantitative guidance was provided.
As of September 30, 2025, the company held $67.1M in cash and $42.3M in short-term investments, providing a combined liquidity of $109.4M. Total debt (net of unamortized costs) stood at $59.2M, a slight decrease of $0.6M from June 30, 2025. Shareholders' equity increased to $249.8M from $237.9M, driven by net income and contributions from joint venture partners.
No purchase commitments were disclosed in the Notes. The company disclosed professional liability and litigation contingencies, including a $10.1M accrual for the Securities Action settlement, but no specific purchase obligations.
No share repurchases or dividends were executed during the quarter. The company issued $60.1M of debt (Term Loan A Facility refinancing) and repaid $60.0M, resulting in a net decline of $0.6M in debt. Capital expenditures totaled $4.1M (1.7% of revenue), primarily for property and equipment.
The company operates as one reportable segment, PACE, which generated $235.8M in revenue (99.9% of total). Center-Level Contribution Margin for PACE was $51.3M, up from $34.4M in the prior year quarter, reflecting improved operational efficiency. The immaterial 'Other' segment (Senior Housing) contributed $0.3M revenue.
Operating cash flow (CFO) of $3.9 million exceeded net income of $7.7 million due to significant working capital uses, particularly a $24.3 million decrease in accounts payable and accrued expenses, partially offset by a $13.2 million decrease in accounts receivable. This indicates strong cash conversion from receivables but a timing drag from payables. Capex increased to $4.1 million from $2.2 million, reflecting higher investment in property and equipment. Free cash flow, not explicitly stated, would be negative $0.2 million (CFO minus capex), suggesting reliance on external financing. The company had no share repurchases or dividends in the quarter, and financing activities were negligible. The prior year showed a net loss and negative CFO, highlighting a significant turnaround in cash generation.